Disc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 38.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,560 shares of the company’s stock after acquiring an additional 5,458 shares during the period. Teachers Retirement System of The State of Kentucky owned 0.07% of Disc Medicine worth $961,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Amalgamated Bank grew its position in shares of Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after purchasing an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after buying an additional 337 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Disc Medicine by 2.7% during the third quarter. The Manufacturers Life Insurance Company now owns 29,065 shares of the company’s stock worth $1,428,000 after buying an additional 771 shares during the last quarter. SG Americas Securities LLC grew its holdings in Disc Medicine by 19.5% in the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company’s stock valued at $239,000 after buying an additional 793 shares in the last quarter. Finally, TD Asset Management Inc increased its stake in shares of Disc Medicine by 3.7% in the 2nd quarter. TD Asset Management Inc now owns 40,732 shares of the company’s stock worth $1,836,000 after acquiring an additional 1,468 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Insider Activity

In related news, insider William Jacob Savage sold 9,158 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $59.64, for a total transaction of $546,183.12. Following the sale, the insider now directly owns 40,405 shares of the company’s stock, valued at $2,409,754.20. This represents a 18.48 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William Richard White sold 7,136 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,627 shares of company stock valued at $2,883,150. 4.24% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

IRON has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a research report on Monday, December 9th. Jefferies Financial Group started coverage on shares of Disc Medicine in a research note on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 price target for the company. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target for the company in a report on Tuesday, November 5th. Raymond James upgraded Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $66.00 to $110.00 in a report on Monday, November 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, October 15th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $87.50.

Disc Medicine Stock Down 2.3 %

IRON opened at $63.50 on Thursday. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The business has a fifty day simple moving average of $58.19 and a 200-day simple moving average of $50.24. The firm has a market cap of $1.89 billion, a P/E ratio of -15.95 and a beta of 0.76.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15. Sell-side analysts expect that Disc Medicine, Inc. will post -4.05 earnings per share for the current year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.